Canada's Drug Agency has recently made a pivotal recommendation regarding the funding of lecanemab, a treatment designed to slow the progression of early-stage Alzheimer’s disease. The agency has suggested that public drug plans should consider covering this treatment for eligible patients, contingent upon specific criteria being met.
Lecanemab is an antibody that specifically targets the accumulation of amyloid plaque in the brain, which is thought to be a fundamental cause of Alzheimer’s disease. Although Health Canada granted approval for lecanemab in October 2022, Canada's Drug Agency initially recommended against its public funding in February 2023. The agency's concerns stemmed from the treatment's effectiveness and potential side effects, notably brain swelling or bleeding.
In response to a request from Eisai, the drug’s manufacturer, the agency's expert committee revisited its earlier decision. They concluded that the potential clinical significance of lecanemab had been underestimated. In an updated recommendation released on Thursday, the agency acknowledged the challenges faced by patients with early Alzheimer’s, who confront a progressive and ultimately debilitating condition with limited treatment options available.
To qualify for treatment with lecanemab, patients must meet several criteria: they must exhibit only mild cognitive impairment, have a confirmed presence of amyloid protein as indicated by a brain scan or cerebrospinal fluid analysis, and undergo regular MRI assessments to monitor for any signs of brain swelling or bleeding.
The recommendation emphasizes the importance of patient autonomy, allowing individuals to make informed decisions about their treatment in collaboration with their healthcare providers. It was also noted that if a patient’s condition deteriorates from mild cognitive impairment to moderate dementia, the drug should no longer be publicly covered, as current studies have only demonstrated the treatment's effectiveness in early-stage Alzheimer’s disease.
Alzheimer's societies across Canada have been advocating for public funding for lecanemab, which is also marketed under the brand name Leqembi. These organizations argue that the drug could prolong the period during which patients enjoy better cognitive function, enabling them to share more quality time with their loved ones before the inevitable progression of dementia.
Despite the concerns surrounding the potential side effects of lecanemab, some dementia experts have suggested that the incidents of brain swelling or bleeding are usually minor and do not lead to significant symptoms, even if such issues are detectable on MRI scans.
The financial aspect of lecanemab is also noteworthy, as the Canadian Consortium on Neurodegeneration in Aging reports that the treatment comes at an approximate cost of $32,000 per year. The treatment is administered intravenously every two to four weeks, as stated on the consortium's official website.
